Koyfin Home > Directory > Health Care > Aduro Biotech > Preferred Equity

Aduro Biotech Preferred Equity Chart (ADRO)

Aduro Biotech annual/quarterly Preferred Equity from 2013 to 2015.
  • Aduro Biotech Preferred Equity for the quarter ending March 03, 2015 was $166m a 80.55% increase of 134m year over year
  • Aduro Biotech Preferred Equity for the last 12 months ending March 03, 2015 was $166m a 80.55% increase of 134m year over year
  • Aduro Biotech Annual Preferred Equity for 2014 was $140m a 76.94% increase of 108m from 2013
  • Aduro Biotech Annual Preferred Equity for 2013 was $32m a 26.39% increase of 9m from 2012
  • Aduro Biotech Annual Preferred Equity for 2012 was $24m
Other Balance Sheet Metrics:
  • Aduro Biotech Total Assets for the quarter ending December 12, 2018 was $358m a -18.27% decrease of -65m year over year
  • Aduro Biotech Other Liabilities for the quarter ending December 12, 2018 was $192m a 1.13% increase of 2m year over year
  • Aduro Biotech Total Equity for the quarter ending December 12, 2018 was $135m a -45.56% decrease of -62m year over year
View Chart On Koyfin

Quarterly ADRO Preferred Equity Data

03/2015$166m
12/2014$140m
09/2014$83m
03/2014$32m
12/2013$32m

Annual ADRO Preferred Equity Data

2014$140m
2013$32m
2012$24m